Clinical Trials Directory

Trials / Unknown

UnknownNCT00161096

On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication

Comparison of the Percentage Chronic on-Demand Users Treated With 20 Mg Pantoprazole on-Demand and Placebo o.d Versus Placebo on-Demand and 20 Mg Pantoprazole o.d. After Symptom Relief With 20 Mg Pantoprazole o.d.

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
276 (planned)
Sponsor
UMC Utrecht · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate several aspects of chronic use of acid suppressing medication: dependence on maintenance therapy, the possibilities for on-demand use, and predictors (patient characteristics) for daily need, for on-demand use and for termination of chronic use.

Detailed description

2-5% of the general population is chronic user of acid suppressing medication (proton pump inhibitors, H2 receptor antagonists), mostly because of gastro-oesophageal reflux disease (GORD). Prescription data from health insurances show that the number of chronic users increases every year, which has large economic consequences. There are indications however that on-demand and intermittent therapy can be as effective as daily use. No evidence exists regarding patients who are likely to benefit from intermittent, on-demand therapy or even termination. In this study several aspects of chronic use of acid suppressive therapy are investigated in family practice patients. Chronic users are transferred to pantoprazole 20 mg for 4 weeks. Patients with adequate relief of symptoms are randomized in two groups for a period of 13 weeks. group 1: daily pantoprazole 20 mg, placebo on-demand (indicative for placebo-dependency) group 2: daily placebo, pantoprazole 20 mg on-demand (indicative for pharmacological dependency) Patients visit the research nurse at the beginning of the study and at week 4, 5, 10 and 17. In this study we are looking for patient characteristics indicative for the dependency on acid suppressive drugs and for possibilities to reduce the dose of these drugs. Furthermore, aspects described in "secondary outcomes" will be addressed.

Conditions

Interventions

TypeNameDescription
DRUGpantoprazole 20 mg (drug)

Timeline

Start date
2004-03-01
Completion
2005-09-01
First posted
2005-09-12
Last updated
2006-02-02

Source: ClinicalTrials.gov record NCT00161096. Inclusion in this directory is not an endorsement.